| An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" |
Completed |
TKI258 / Sorafenib |
3 |
CTKI258A2302 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) |
Ongoing |
Tezepelumab |
3 |
D5180C00018 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh) |
| Comparison of the Efficacy and Safety for different regimen of Venous Thromboembolism pharmacoprophylaxis among Severely Burn Patients: A Multicenter, Randomized Controlled Trial |
Ongoing |
HEPARIN SODIUM, ENOXAPARIN SODIUM |
4 |
RC18/400/R |
King Abdulaziz Medical City NG (Riyadh) |
| Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis |
Ongoing |
Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care |
4 |
1F-MC-B007 |
Hira Hospital (Makkah) |
| Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma |
Ongoing |
DUPILUMAB |
4 |
LPS15834 |
King Fahad Medical City (Riyadh) |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS |
Ongoing |
DUPILUMAB |
4 |
OBS15990 |
King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) |
Ongoing |
Drug choice as per treating physician which is not limited per the protocol |
4 |
H19-940 |
Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Multinational, Prospective, Observational Study of theEffectiveness, Healthcare Resource Utilization and Costsin Patients with Rheumatoid Arthritis ReceivingBaricitinib, Targeted Synthetic or BiologicDisease-Modifying Therapies" |
Ongoing |
Baricitinib |
4 |
I4V-MCB009 |
Specialized Medical Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Takhassusi (Riyadh) |
| A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with Type 2 diabetes mellitus, treated with iGlarLixi fixed ratio combination (SOLIQUA®) before, during and after the period of Ramadan (SoliRam Study) |
Ongoing |
Soliqua® Solostar |
4 |
OBS16049 |
University District Hospital (Jeddah), Alzafer Hospital (Najran), Ghassan Najeeb Pharaon hospital (Jeddah) |
| Guidelines Oriented Approach to Lipid lowering Quality Enhancement Research Initiative (GOAL QuERI) International |
Ongoing |
any SFDA registered anti-hyperlipidemic product |
4 |
CHRC2019 |
King Fahd Armed Forces Hospital (Jeddah), King Fahd Military Medical Complex (Dhahran), King Abdullah Medical Complex (Jeddah), King Fahad Hospital (Jeddah), King Fahad Genaral Hospital (Medina), King Khaled General Hospital (Hafar Al Batin), Royal Commission Hospital Jubail |
